Drug development halted after reports of pancreatic inflammation.
April 04 2006 3:25 PM EST
April 04 2006 8:00 PM EST
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Drug development halted after reports of pancreatic inflammation.
Pharmaceutical company Incyte on Monday announced that it has halted developed on its experimental HIV nucleoside reverse transcriptase inhibitor DFC, formerly known as Reverset, because the drug boosted risks for pancreatic inflammation. Researchers noted an increased level of grade 4 hyperlipasemia, a marker of pancreatic inflammation, in the Phase II-b study. Based on the study findings, Incyte announced it has halted enrollment in the clinical trial and will begin working with the Food and Drug Administration to find alternative treatments for the study participants who have drug-resistant virus and few other treatment options. (The Advocate)